Role of interleukin‑32 in cancer progression (Review)

Danyang Meng; Hang Dong; Chennan Wang; Rongjia Zang; Jianjie Wang

doi:10.3892/ol.2023.14187

Role of interleukin‑32 in cancer progression (Review)

Oncol Lett. 2023 Dec 12;27(2):54. doi: 10.3892/ol.2023.14187. eCollection 2024 Feb.

Authors

Danyang Meng¹, Hang Dong², Chennan Wang¹, Rongjia Zang³, Jianjie Wang¹

Affiliations

¹ School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
² Department of Hematology, Shenzhen Yantian District People's Hospital, Shenzhen, Guangdong 518081, P.R. China.
³ Department of Anesthesiology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China.

Abstract

Interleukin (IL)-32 is induced by pro-inflammatory cytokines and promotes the release of inflammatory cytokines. Therefore, it can promote inflammatory responses. The present review article summarized the role of the receptors required for IL-32 action, the biological function of IL-32 and its mechanism of action in tumors. Moreover, it assessed the significance of aberrant IL-32 expression in associated diseases and analyzed the effects of IL-32 on four key types of cancer: Colorectal, gastric, breast and lung. However, the mechanism of action of IL-32 needs to be further demonstrated by assessing the role of this cytokine in cancer to elucidate novel and reliable targets for future cancer treatments.

Keywords: breast cancer; colorectal cancer; gastric cancer; interleukin-32; lung cancer.

Publication types

Review

Grants and funding

The present study was supported by Natural Science Foundation of Heilongjiang Province (grant no. LH2021H106) and the Basic Research Fund of Universities of Heilongjiang Province (grant no. 2021-KYYWF-0598).